Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study
Table 1
Baseline characteristics and medications of study participants* ().
Switch-to-rosuvastatin 40 mg
Add-on-statin ER-NA/laropiprant
N (females/males)
30 (17/13)
30 (16/14)
NS
Age (years)
62 ± 10
58 ± 14
NS
Current smokers (%)
7 (23)
10 (33)
NS
Diabetes mellitus (%)
4 (13)
6 (20)
NS
Metabolic syndrome (%)
15 (50)
16 (53)
NS
Body weight (kg)
79 ± 10
81 ± 10
NS
BMI (kg/m2)
29.1 ± 2.5
29.1 ± 3.1
NS
Waist circumference (cm)
102 ± 8
99 ± 8
NS
SBP (mmHg)
127 ± 14
134 ± 12
NS
DBP (mmHg)
80 ± 7
81 ± 9
NS
Hypertensive subjects (%)
15 (50)
18 (60)
NS
TC (mg/dL)
226 ± 36
202 ± 42
NS
(mmol/L)
5.8 ± 0.9
5.2 ± 1.1
Triglycerides (mg/dL)
169 (150–189)
164 (141–187)
NS
(mmol/L)
1.9 (1.7–2.1)
1.9 (1.6–2.1)
HDL-C (mg/dL)
55 ± 9
47 ± 11
NS
(mmol/L)
1.4 ± 0.2
1.2 ± 0.3
LDL-C (mg/dL)
142 ± 45
112 ± 35
NS
(mmol/L)
3.7 ± 1.2
2.9 ± 0.9
Non-HDL-C (mg/dL)
175 ± 33
155 ± 37
NS
(mmol/L)
4.5 ± 0.9
4.0 ± 1
Medications at baseline
Aspirin
9
8
NS
Beta blockers
8
8
NS
HCTZ
10
11
NS
ACEIs/ARBs
12
14
NS
Calcium channel blockers
7
9
NS
Metformin
10
9
NS
Pioglitazone
2
1
NS
Sulfonylurea
4
5
NS
Insulin
4
3
NS
Atorvastatin 5–20 mg/day
10
9
NS
Simvastatin 10–40 mg/day
13
9
NS
Rosuvastatin 5–20 mg/day
7
12
NS
ER-NA: extended release nicotinic acid, NS: not significant, BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: total cholesterol, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, HCTZ: hydrochlorothiazide, ACEIs: angiotensin converting enzyme inhibitors, ARBs: angiotensin receptor blockers. *Values are expressed as mean ± standard deviation (except for triglycerides which are expressed as median (range)).
